X4医薬品は,レアレアの血液病治療の資金を調達するため,株の供与金として1億550万5,300万ドルを引き上げた. X4 Pharmaceuticals raised $155.3 million in a stock offering to fund rare blood disease treatments.

X4 Pharmaceuticalsは2025年10月27日に公開取引を終了し,2,90ドルで528万株を売却し,総収益1553万ドルを調達し,承諾者は698万株の追加購入オプションを完全に行使した. X4 Pharmaceuticals closed a public offering on October 27, 2025, raising $155.3 million in gross proceeds by selling 52.8 million shares at $2.90 each, with underwriters fully exercising their option to buy an additional 6.98 million shares. 特定の投資家は,各2.899ドルで700,000株の事前資金調達ウォーラントを受け取り,株当たり0.001ドルで行使可能であった. Certain investors received pre-funded warrants for 700,000 shares at $2.899 each, exercisable at $0.001 per share. この会社は,XFORとしてナスダックで取引されており,研究,臨床開発,および希少血液病の治療法の商業化に資金を使用する予定です. The company, trading on Nasdaq as XFOR, plans to use the funds for research, clinical development, and commercialization of therapies for rare hematology diseases.